DS Research in the News- Brandi’s Story

by

Meet Brandi — one of our incredible alopecia areata patients who’s been using her voice to spread awareness nationwide. In this interview, she shares her journey with alopecia, the challenges it brings, and how treatment completely changed her life. What many don’t see behind the scenes is how clinical trials made this possible. Brandi participated… Read More

Milestone Achievement: FDA Approves ZORYVE® Cream 0.05% for Ages 2–5

by

Milestone Achievement: FDA Approves ZORYVE® Cream 0.05% for Ages 2–5 We’re proud to share that the U.S. Food and Drug Administration has approved ZORYVE® (roflumilast) cream 0.05% for the treatment of mild to moderate atopic dermatitis in children ages 2 to 5. This is a major step forward for dermatologic care in very young children—and we’re honored to… Read More

Advancing Hair Loss Treatments: DS Research Supports Trials of First-in-Class Oral Therapy VDPHL01

by

DS Research is proud to be a participating site in Veradermics’ ongoing clinical trials evaluating VDPHL01, a first-in-class, non-hormonal oral treatment for androgenetic alopecia (pattern hair loss). These trials represent a significant step forward in addressing hair loss for both men and women. The Phase 2/3 study for male patients is a randomized, double-blind, placebo-controlled trial enrolling approximately 480 participants across 44 sites in… Read More

DS Research Contributes to FDA Approval of Leqselvi™ for Severe Alopecia Areata

by

DS Research was proud to be a participating site in the pivotal clinical trials that led to the FDA approval of Leqselvi™ (deuruxolitinib) for adults with severe alopecia areata. The drug was studied in two large Phase 3 trials—THRIVE-AA1 and THRIVE-AA2—which enrolled over 1,200 patients experiencing significant scalp hair loss. In these trials, participants received 8 mg or 12 mg of Leqselvi twice daily for 24… Read More

Patient Spotlight – Breakthrough in Alopecia Areata

by

We’re proud to share that one of our patients was recently featured in Women’s Health, highlighting the impact of groundbreaking new treatments for alopecia areata—a condition where the immune system mistakenly attacks hair follicles, causing patchy or complete hair loss. The article explores how a new class of medications, known as JAK inhibitors, is offering hope… Read More

2024 Dermatology Advancements: FDA Approvals, Breakthrough Treatments & Innovative Diagnostic Tools

by

2024: A Landmark Year in Dermatology AdvancementsThe field of dermatology has witnessed an exciting leap forward in 2024 with the approval of groundbreaking drugs and devices that are reshaping the treatment landscape for a wide variety of skin conditions. From advanced melanoma therapies to cutting-edge psoriasis and acne treatments, the dermatology sector is benefiting from… Read More

Exploring the Connection Between Alopecia Areata and Hearing Impairment 

by

Overview of Research Objectives  A recent study published in Cureus has shed light on a significant yet less explored domain: the relationship between alopecia areata (AA) and auditory dysfunction. This research seeks to unravel the intricate links between these two conditions, offering new insights into the comprehensive healthcare needs of individuals with AA.  Significance of… Read More

Introduction to Secukinumab’s FDA Approval

by

A Milestone in Hidradenitis Suppurativa Treatment The medical community welcomed a groundbreaking advancement with the FDA’s recent approval of Secukinumab (Cosentyx) for treating hidradenitis suppurativa (HS). This approval marks a significant development, as Secukinumab is the first new biologic therapy for HS in nearly a decade. Hidradenitis suppurativa, a chronic and often debilitating skin condition,… Read More

The Crucial Role of Inclusion Clinical Trials for Equitable Treatment Options

by

Psoriasis affects millions worldwide, with symptoms ranging from mild to severe. Critical to advancing treatments for this diverse condition are clinical trials. They are the engines driving medical innovations, particularly in dermatology. Our focus today is on the study “Differential Patient Travel Distance and Time to Psoriasis Clinical Trial Sites,” which sheds light on the… Read More

Understanding Mental Health as a Psoriasis Comorbidity

by

As common as Psoriasis is, the comorbidities associated with Psoriasis are often overlooked by patients and sometimes their physicians. As a part of their Psoriasis comorbidities series, Delaney Drew, and Kristi Hawley, DO have been publishing monthly articles to better identify, understand, and associate these issues. In part 2 published in October, mental health comes… Read More